CN110505902B - 普利多匹定用于治疗脆性x综合征的应用 - Google Patents

普利多匹定用于治疗脆性x综合征的应用 Download PDF

Info

Publication number
CN110505902B
CN110505902B CN201880007913.2A CN201880007913A CN110505902B CN 110505902 B CN110505902 B CN 110505902B CN 201880007913 A CN201880007913 A CN 201880007913A CN 110505902 B CN110505902 B CN 110505902B
Authority
CN
China
Prior art keywords
pridopidine
subject
fxs
acid
vigabatrin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880007913.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN110505902A (zh
Inventor
迈克尔·海登
马哈茂德·阿卜杜勒侯赛因·普拉迪
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prenia Neurotherapy Co ltd
Agency for Science Technology and Research Singapore
National University of Singapore
Original Assignee
Prenia Neurotherapy Co ltd
Agency for Science Technology and Research Singapore
National University of Singapore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prenia Neurotherapy Co ltd, Agency for Science Technology and Research Singapore, National University of Singapore filed Critical Prenia Neurotherapy Co ltd
Publication of CN110505902A publication Critical patent/CN110505902A/zh
Application granted granted Critical
Publication of CN110505902B publication Critical patent/CN110505902B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
CN201880007913.2A 2017-01-20 2018-01-18 普利多匹定用于治疗脆性x综合征的应用 Active CN110505902B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762448595P 2017-01-20 2017-01-20
US62/448,595 2017-01-20
PCT/US2018/014169 WO2018136600A1 (en) 2017-01-20 2018-01-18 Use of pridopidine for the treatment of fragile x syndrome

Publications (2)

Publication Number Publication Date
CN110505902A CN110505902A (zh) 2019-11-26
CN110505902B true CN110505902B (zh) 2022-11-11

Family

ID=62908348

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880007913.2A Active CN110505902B (zh) 2017-01-20 2018-01-18 普利多匹定用于治疗脆性x综合征的应用

Country Status (13)

Country Link
US (2) US11234973B2 (cg-RX-API-DMAC7.html)
EP (1) EP3570940B1 (cg-RX-API-DMAC7.html)
JP (1) JP7114604B2 (cg-RX-API-DMAC7.html)
CN (1) CN110505902B (cg-RX-API-DMAC7.html)
AU (1) AU2018210145B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019015000A2 (cg-RX-API-DMAC7.html)
CA (1) CA3050700C (cg-RX-API-DMAC7.html)
DK (1) DK3570940T3 (cg-RX-API-DMAC7.html)
ES (1) ES2972205T3 (cg-RX-API-DMAC7.html)
HU (1) HUE068300T2 (cg-RX-API-DMAC7.html)
IL (1) IL268125B2 (cg-RX-API-DMAC7.html)
PL (1) PL3570940T3 (cg-RX-API-DMAC7.html)
WO (1) WO2018136600A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013536825A (ja) 2010-09-03 2013-09-26 イバックス・インターナショナル・ゲーエムベーハー ドパミン作動性安定化剤として有用なプリドピジンの重水素化類似体
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
EP3503890B1 (en) 2016-08-24 2024-12-18 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating dystonias
MX390627B (es) 2016-08-24 2025-03-21 Prilenia Neurotherapeutics Ltd Uso de pridopidina para el tratamiento de la disminucion funcional.
US12102627B2 (en) 2016-09-16 2024-10-01 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating rett syndrome
US12036213B2 (en) 2017-09-08 2024-07-16 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias
CN111343982A (zh) 2017-09-08 2020-06-26 普瑞尼亚神经治疗有限公司 用于治疗药物诱发的异动症的普利多匹定
BR112021015346A2 (pt) 2019-02-04 2021-10-05 Prilenia Neurotherapeutics Ltd. Uso de pridopidina de baixa dose para a doença de parkinson e outras doenças associadas ao parkinsonismo
JP7490064B2 (ja) * 2020-01-08 2024-05-24 ニューロヴェンティ カンパニー リミテッド リスリード化合物を有効成分として含む脆弱ｘ症候群または関連発達障害治療用組成物
CN116472043A (zh) * 2020-10-20 2023-07-21 普瑞尼亚神经治疗有限公司 普利多匹定和类似物用于治疗焦虑和抑郁的用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9904724D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
CA2584831C (en) 2004-10-13 2013-09-17 Neurosearch Sweden Ab Process for the synthesis of 4-(3-methanesulfonylphenyl)-1-n-propyl-piperidine
WO2008127188A1 (en) 2007-04-12 2008-10-23 Allbay Ab N-oxide and/or di-n-oxide derivatives of dopamine receptor stabilizers/modulators displaying improved cardiovascular side-effects profiles
TW200848063A (en) * 2007-04-23 2008-12-16 Combinatorx Inc Methods and compositions for the treatment of neurodegenerative disorders
JP2013532233A (ja) 2010-07-02 2013-08-15 アクティエボラゲット・エスコーエッフ 機械構成要素、および表面硬化方法
JP2013536825A (ja) 2010-09-03 2013-09-26 イバックス・インターナショナル・ゲーエムベーハー ドパミン作動性安定化剤として有用なプリドピジンの重水素化類似体
PL2667715T3 (pl) * 2011-01-27 2018-02-28 Neuren Pharmaceuticals Limited Leczenie zaburzeń spektrum autystycznego z wykorzystaniem kwasu glicylo-l- 2-metyloprolilo-l-glutaminowego
EP2753603B1 (en) 2011-09-07 2017-06-21 Teva Pharmaceuticals International GmbH Polymorphic form of pridopidine hydrochloride
WO2013086425A1 (en) 2011-12-08 2013-06-13 IVAX International GmbH The hydrobromide salt of pridopidine
US20130267552A1 (en) 2012-04-04 2013-10-10 IVAX International GmbH Pharmaceutical compositions for combination therapy
CN104768545A (zh) * 2012-09-27 2015-07-08 泰华制药工业有限公司 雷沙吉兰和普多比啶组合以治疗神经退化性病症,尤其亨廷顿氏病
UA122999C2 (uk) 2013-06-21 2021-02-03 Прайлінія Н'Юротерапьютікс Лтд. Застосування придопідину для лікування хвороби гантінгтона
JP6949487B2 (ja) 2014-01-22 2021-10-13 プリレニア・ニューロセラピューティクス・エルティーディーＰｒｉｌｅｎｉａ Ｎｅｕｒｏｔｈｅｒａｐｅｕｔｉｃｓ Ｌｔｄ プリドピジンの調節放出製剤
TW201613859A (en) 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
CA2970799A1 (en) 2014-12-22 2016-06-30 Teva Pharmaceuticals International Gmbh L-tartrate salt of pridopidine
EP4282479A3 (en) 2015-02-25 2024-02-21 Prilenia Neurotherapeutics Ltd. Use of pridopidine to treat depression or anxiety
WO2016138135A1 (en) 2015-02-25 2016-09-01 Teva Pharmaceuticals International Gmbh Sigma-1 receptor modulators for treating huntington's disease

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
The sigma-1 receptor mediates the beneficial effects of pridopidine in a mouse model of Huntington disease;Daniel Ryskamp等;《Neurobiol Dis》;20170105;第97卷;46-59 *

Also Published As

Publication number Publication date
JP7114604B2 (ja) 2022-08-08
IL268125B2 (en) 2023-04-01
EP3570940A4 (en) 2020-10-28
PL3570940T3 (pl) 2024-06-17
EP3570940B1 (en) 2023-12-13
IL268125B (en) 2022-12-01
HUE068300T2 (hu) 2024-12-28
DK3570940T3 (da) 2024-02-19
US20220202798A1 (en) 2022-06-30
WO2018136600A1 (en) 2018-07-26
US20190336488A1 (en) 2019-11-07
BR112019015000A2 (pt) 2020-04-07
CA3050700A1 (en) 2018-07-26
EP3570940A1 (en) 2019-11-27
AU2018210145B2 (en) 2023-06-29
AU2018210145A1 (en) 2019-08-29
JP2020514313A (ja) 2020-05-21
IL268125A (en) 2019-09-26
CN110505902A (zh) 2019-11-26
CA3050700C (en) 2023-10-03
US11234973B2 (en) 2022-02-01
ES2972205T3 (es) 2024-06-11

Similar Documents

Publication Publication Date Title
CN110505902B (zh) 普利多匹定用于治疗脆性x综合征的应用
US11406625B2 (en) Method of treating amyotrophic lateral sclerosis with pridopidine
CN109952100A (zh) 普利多匹定用于治疗焦虑和抑郁的用途
Class et al. Patent application title: USE OF PRIDOPIDINE FOR THE TREATMENT OF FRAGILE X SYNDROME Inventors: Michael Hayden (Herzliya, IL) Mahmoud Abdulhossein Pouladi (Singapore, SG) Assignees: PRILENIA NEUROTHERAPEUTICS LTD. NATIONAL UNIVERSITY OF SINGAPORE Agency For Science, Technology and Research
RU2374245C1 (ru) Лиганд с широким спектром одновременной рецепторной активности, фармацевтическая композиция, способ ее получения и лекарственное средство
van Dijk et al. Behavioural effects of trishomocubanes in rats with unilateral 6-hydroxydopamine lesions
HK40016661A (en) Pridopidine for use in the treatment of fragile x syndrome
HK40016661B (en) Pridopidine for use in the treatment of fragile x syndrome
BR122025001464A2 (pt) Uso de pridopidina e, opcionalmente, de um segundo composto para o tratamento de esclerose lateral amiotrófica (ela) e composição farmacêutica
CN114761008A (zh) 用于在患有痴呆的患者中治疗行为和心理症状的方法
HK40071167A (en) Methods for treating behavioral and psychological symptoms in patients with dementia
EA043430B1 (ru) Способ лечения бокового амиотрофического склероза придопидином
Manjunath Study of Effectiveness and Tolerability of Opipramol in the Treatment of Generalized Anxiety Disorder and Somatoform Disorders
TW202132278A (zh) 魯哌啶酮用於治療負性症狀及疾病、增加神經可塑性及促進神經保護的用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant